Advertisement
News
Subscribe to MDT Magazine News

VCA Antech 3Q profit drops, misses expectations

October 22, 2010 2:45 pm | by The Associated Press | Comments

VCA Antech Inc., which owns and operates veterinary hospitals and laboratories and sells premium and therapeutic pet food, said Friday that its third-quarter profit fell 25 percent as costs and expenses rose, missing analyst expectations.For July through September, VCA Antech earned $27.4...

Ventas to buy Atria real estate assets for $1.5B

October 22, 2010 11:45 am | by The Associated Press | Comments

Ventas Inc. said Friday it is buying the real estate assets of Atria Senior Living Group for $1.5 billion in cash and stock, giving it a portfolio of 118 homes located in wealthy coastal regions.The healthcare real estate investment trust is also assuming $1.6 billion in debt.Ventas said the...

Health insurers help GOP after dalliance with Dems

October 22, 2010 10:45 am | by JIM KUHNHENN - Associated Press Writers - Associated Press | Comments

Health insurers flirted with Democrats, supported them with money and got what they wanted: a federal mandate that most Americans carry health care coverage. Now they're backing Republicans, hoping a GOP Congress will mean friendlier regulations.They may get more than they're wishing for.The...

Advertisement

Boston biotech finance head Baia dies

October 22, 2010 10:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Anne Baia, financial advisor and interim chief financial offier for several venture-backed Boston-area life sciences companies, died on Oct. 20 from cancer. She was 54 years old.

Europe approves expanded use of Boston Scientific stent

October 22, 2010 10:33 am | by Mass High Tech: The Journal of New England Technology | Comments

Boston Scientific Corp. has received CE approval in Europe for expanded use of its WallFlex Biliary RX Fully Covered Stent for the treatment of benign bile duct strictures.

Fentanyl Transdermal System: Recall - Potential for Active Ingredient to Release Faster Than Specified

October 22, 2010 10:33 am | by U.S. Food & Drug Administration | Comments

Accelerated release of Fentanyl can lead to adverse events for at-risk patients, including excessive sedation, respiratory depression, hypoventilation, and apnea.

Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing

October 22, 2010 9:33 am | by Bio-Medicine.Org | Comments

BEIJING, Oct. 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS ) ("Lotus" or the "Company"), a fast-growing, profitable developer, manufacturer and seller of medicine and drugs in the People's Republic of China ("PRC"), announced today that the...

TOPICS:

Bacterin International Holdings, Inc. Schedules Conference Call to Present Third Quarter 2010 Financial Results

October 22, 2010 9:33 am | by Bio-Medicine.Org | Comments

BELGRADE, Mont., Oct. 22 /- Bacterin International Holdings, Inc. (OTC Bulletin Board: BIHI ) ("Bacterin"), announced today that it has scheduled a conference call for Monday, November 15, 2010 at 10:00 a.m. (ET) to discuss the Company's financial results for its third quarter 2010, which...

TOPICS:
Advertisement

AdvaMed 2010 Sets New Attendance Record: More than 1,700 Device and Diagnostics Leaders from Across the Country and Around the World Came to Washington, D.C.

October 22, 2010 9:33 am | by Bio-Medicine.Org | Comments

WASHINGTON, Oct. 22 /PRNewswire-USNewswire/ -- More than 1,700 medical device and diagnostics leaders from more than 360 companies – representing 24 countries and 33 states – attended the fourth annual industry gathering, AdvaMed 2010: The MedTech Conference this week in...

TOPICS:

10 Tips for Breast Cancer Survivors

October 22, 2010 9:32 am | by Bio-Medicine.Org | Comments

SEATTLE, Oct. 22 /- Throughout October, National Breast Cancer Awareness Month, experts from Fred Hutchinson Cancer Research Center and its clinical care partner, the Seattle Cancer Care Alliance, are offering weekly research-based tip sheets regarding breast cancer prevention, screening...

TOPICS:

Studies: Pneumonia is misdiagnosed on patient readmissions

October 22, 2010 9:32 am | by EurekAlert | Comments

(Henry Ford Health System) Patients were misdiagnosed with pneumonia at an alarming rate when they were readmitted to the hospital shortly after a previous hospitalization for the same illness, according to two Henry Ford Hospital companion studies.

TOPICS:

Pharmaxis Announces Positive Combined Phase 3 Cystic Fibrosis Trial Results

October 22, 2010 9:32 am | by Bio-Medicine.Org | Comments

BALTIMORE, Oct. 22 /- Pharmaceutical company Pharmaxis (ASX: PXS) today announced significant results of pooled data from its two large scale six month Phase III trials of Bronchitol (inhaled mannitol) in people with cystic fibrosis. The combined results have been presented for the first...

TOPICS:

Boston Scientific Announces CE Mark Approval for Expanded Indication of WallFlex® Biliary RX Stent

October 22, 2010 8:31 am | by Bio-Medicine.Org | Comments

NATICK, Mass., Oct. 22 /- Boston Scientific Corporation (NYSE: BSX ) today announced that its WallFlex® Biliary RX Fully Covered Stent has received CE Mark approval for the treatment of benign biliary strictures.   "The WallFlex Biliary RX Fully Covered Stent has proved...

TOPICS:

GE Healthcare to Acquire Cancer Diagnostic Company Clarient Inc.

October 22, 2010 8:31 am | by Bio-Medicine.Org | Comments

CHALFONT ST GILES, UK and ALISO VIEJO, Calif., Oct. 22 /- GE Healthcare, a unit of General Electric Company (NYSE: GE ), and Clarient, Inc. (Nasdaq: CLRT ) announced today that they have entered into a definitive agreement for GE Healthcare to acquire Clarient, a leading player in the...

TOPICS:

Summary Box: GE to buy diagnostics firm Clarient

October 22, 2010 7:45 am | by The Associated Press | Comments

THE DEAL: General Electric Co. said its healthcare unit will buy diagnostics company Clarient Inc. to speed its expansion into cancer diagnostic and therapy selection tools.THE PARTICULARS: GE will start a cash tender offer of $5 per share for Clarient common stock and $20 for each preferred share....

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading